Brought to you by 
Creabilis brings in €15mm through its Series B venture round
07 Oct 2011
Executive Summary
Creabilis SA (dermatology, immunology, and pain therapeutics) has raised €15mm ($20mm) through its Series B venture round. Abbott Biotech Ventures led and was joined by current shareholders NeoMed Management, Sofinnova Partners, and private Italian investors. The company will use the funds to continue developing its lead drug candidate, Phase IIa CT327 for psoriasis and atopic dermatitis, to the end of Phase II.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Creabilis brings in €15mm through its Series B venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice